*:Co-first author; #:Co-corresponding author
1. Wang L, Zeng D, Wang Q, Liu L, Lu T, Gao Y. Screening and identification of novel potential biomarkers for breast cancer brain metastases, Front Oncol, 2022, 11:784096. DOI: 10.3389/fonc.2021.784096
2. Dai H*, Xu W*, Wang L*, Li X*, Sheng X, Zhu L, Li Y, Dong X, Zhou W, Han C#, Mao Y#, Yao L#. Loss of SPRY2 contributes to cancer-associated fibroblasts activation and promotes breast cancer development, Breast Cancer Res, 2023, 25(1):90. DOI: 10.1186/s13058-023-01683-8.
3. An J*, Wang L*, Zhao Y, Hao Q, Zhang Y, Zhang J, Yang C, Liu L, Wang W, Fang D, Lu T, Gao Y. Effects of FSTL1 on cell proliferation in breast cancer cell line MDA-MB-231 and its brain metastatic variant MDA-MB-231-BR, Oncol Rep, 2017, 38(5):3001-3010. DOI: 10.3892/or.2017.6004
4. Shi T*, Li X*, Zheng J*, Duan Z, Ooi YY, Gao Y, Wang Q, Yang J#, Wang L#, Yao L#. Increased SPRY1 expression activates NF-κB signaling and promotes pancreatic cancer progression by recruiting neutrophils and macrophages through CXCL12-CXCR4 axis. Cell Oncol (Dordr), 2023, 46(4):969-985. DOI: 10.1007/s13402-023-00791-z